Drug Trial Radar · NCT00888940
Outcomes and Safety Trial Investigating Ecallantide's Effect on Reducing Surgical Blood Loss Volume in Subjects at High Risk of Bleeding Exposed to Cardio-pulmonary Bypass During Cardiac Surgery
Last checked: Nov 20, 2026Latest source record: Aug 10, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
243
Actual
Start
Jun 2009
Primary completion
Dec 2009
Study completion Jan 2010
Sponsor
- Lead sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Industry
- Sponsor type
- Industry
- First posted
- Apr 28, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 2 Randomized Double-Blind Active-Controlled Study in Subjects Exposed to Cardio-pulmonary Bypass During Cardiac Surgery at High Risk of Bleeding
Conditions
- Bloodloss
- Surgical Procedures, Operative
Interventions
EcallantideDrug
2.25 mg/L pump prime, 0.13 mg/kg loading dose, 2.25 mg/L constant infusion
Cyklokapron(R)Drug
1000-mg loading dose followed by a continuous infusion of 400 mg/hr with an additional 500 mg added to the pump prime
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cumulative Volume of Packed Red Blood Cells TransfusedTime frame: 12 hours after the end of surgery
Locations
34 sites in 3 countries. Site status is shown where the registry gives one.
Cardio-Thoracic Surgeons PC
Birmingham, Alabama
Universitaetsklinikum Aachen AoeR
Aachen, Germany
Klinikum Augsburg
Augsburg, Germany
Herz- und Gefaesszentrum Bad Bevensen
Bad Bevensen, Germany
Universitaetsklinikum Bonn
Bonn, Germany
Klinik und Poliklinik fuer Herz- und Thoraxchirurgie der Universitaet zu Koeln
Cologne, Germany
St. Johannes Hospital
Dortmund, Germany
Herzzentrum Dresden GmbH Universitaetsklinik
Dresden, Germany
Universitaetsklinikum Erlangen
Erlangen, Germany
Universitaetsklinikum Frankfurt
Frankfurt, Germany
Universitaetsklinikum Freiburg
Freiburg im Breisgau, Germany
Universitaetsmedizin Goettingen
Göttingen, Germany
Universitaetsklinikum Halle (Saale)
Halle, Germany
Universitaeres Herzzentrum Hamburg GmbH
Hamburg, Germany
Universitaetsklinikum Heidelberg
Heidelberg, Germany
Herzzentrum Leipzig GmbH
Leipzig, Germany
Klinik fuer Herzchirurgie des Universitaetsklinikum SH
Lübeck, Germany
Klinikum der Stadt Ludwigshafen gGmbH
Ludwigshafen, Germany
Deutsches Herzzentrum Muenchen
Munich, Germany
HELIOS Klinik Wuppertal
Wuppertal, Germany
Universitaetsklinikum Wuerzburg
Würzburg, Germany
Uniwersytecki Szpital Kliniczny w Bialymstoku
Bialystok, Poland
Szpital Uniwersytecki im. Dr. Antoniego Jurasza w Bydgoszczy
Bydgoszcz, Poland
Akademickie Centrum Kliniczne, Szpital AM w Gdansku
Gdansk, Poland
Samodzielny Publiczny Szpital Kliniczny nr 7 Slaskiego Uniwersytetu Medycznego w Katowicach
Katowice, Poland
Krakowski Szpital Specjalistyczny im. Jana Pawla II
Krakow, Poland
Uniwersytecki Szpital Kliniczny Nr. 3 im. Dr Seweryna Sterlinga
Lódz, Poland
Katedra Chorób Serca AM, Szpital Miejski im. J Strusia
Poznan, Poland
Samodzielny Publiczny Szpital Kliniczny Nr 2 Pomorskiej Akademii Medycznej
Szczecin, Poland
Wojskowy Instytut Medyczny, Centralny Szpital Kliniczny MON
Warsaw, Poland
Instytut Kardiologii im. Prymasa Tysiclecia Stefana Kardynała Wyszyńskiego
Warsaw, Poland
Samodzielny Publiczny Szpital Kliniczny nr 1 we Wroclawiu
Wroclaw, Poland
4 Wojskowy Szpital Kliniczny z Poliklinika SP ZOZ, Centrum Chorób Serca
Wroclaw, Poland
Slaskie Centrum Chorób Serca
Zabrze, Poland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.